vs
American Water Works（AWK）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
American Water Works的季度营收约是Revvity的1.6倍（$1.3B vs $772.1M），American Water Works净利率更高（18.7% vs 12.7%，领先6.0%），Revvity同比增速更快（5.9% vs 5.8%），Revvity自由现金流更多（$161.8M vs $-385.0M），过去两年American Water Works的营收复合增速更高（12.6% vs 9.0%）
American Water Works通过旗下子公司在美国境内提供专业供水与污水处理服务，业务覆盖14个州的约1700个社区，服务约340万活跃用户，客户群体涵盖住宅用户、食品饮料供应商、商业地产开发商与运营商、能源供应商等商业客户、消防服务及工业类客户等。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AWK vs RVTY — 直观对比
营收规模更大
AWK
是对方的1.6倍
$772.1M
营收增速更快
RVTY
高出0.0%
5.8%
净利率更高
AWK
高出6.0%
12.7%
自由现金流更多
RVTY
多$546.8M
$-385.0M
两年增速更快
AWK
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $238.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 31.9% | 14.5% |
| 净利率 | 18.7% | 12.7% |
| 营收同比 | 5.8% | 5.9% |
| 净利润同比 | -0.4% | 3.9% |
| 每股收益（稀释后） | $1.22 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AWKRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.5B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M | ||
| Q1 24 | $1.0B | $649.9M |
净利润AWKRVTY
| Q4 25 | $238.0M | $98.4M | ||
| Q3 25 | $379.0M | $46.7M | ||
| Q2 25 | $289.0M | $53.9M | ||
| Q1 25 | $205.0M | $42.2M | ||
| Q4 24 | $239.0M | $94.6M | ||
| Q3 24 | $350.0M | $94.4M | ||
| Q2 24 | $277.0M | $55.4M | ||
| Q1 24 | $185.0M | $26.0M |
毛利率AWKRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率AWKRVTY
| Q4 25 | 31.9% | 14.5% | ||
| Q3 25 | 42.2% | 11.7% | ||
| Q2 25 | 38.4% | 12.6% | ||
| Q1 25 | 32.7% | 10.9% | ||
| Q4 24 | 33.3% | 16.3% | ||
| Q3 24 | 40.9% | 14.3% | ||
| Q2 24 | 39.4% | 12.4% | ||
| Q1 24 | 32.5% | 6.8% |
净利率AWKRVTY
| Q4 25 | 18.7% | 12.7% | ||
| Q3 25 | 26.1% | 6.7% | ||
| Q2 25 | 22.7% | 7.5% | ||
| Q1 25 | 18.1% | 6.4% | ||
| Q4 24 | 19.9% | 13.0% | ||
| Q3 24 | 26.4% | 13.8% | ||
| Q2 24 | 24.3% | 8.0% | ||
| Q1 24 | 18.4% | 4.0% |
每股收益（稀释后）AWKRVTY
| Q4 25 | $1.22 | $0.86 | ||
| Q3 25 | $1.94 | $0.40 | ||
| Q2 25 | $1.48 | $0.46 | ||
| Q1 25 | $1.05 | $0.35 | ||
| Q4 24 | $1.22 | $0.77 | ||
| Q3 24 | $1.80 | $0.77 | ||
| Q2 24 | $1.42 | $0.45 | ||
| Q1 24 | $0.95 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.0M | $919.9M |
| 总债务越低越好 | $12.8B | — |
| 股东权益账面价值 | $10.8B | $7.3B |
| 总资产 | $35.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.18× | — |
8季度趋势，按日历期对齐
现金及短期投资AWKRVTY
| Q4 25 | $98.0M | $919.9M | ||
| Q3 25 | $166.0M | $931.4M | ||
| Q2 25 | $94.0M | $991.8M | ||
| Q1 25 | $114.0M | $1.1B | ||
| Q4 24 | $96.0M | $1.2B | ||
| Q3 24 | $127.0M | $1.2B | ||
| Q2 24 | $48.0M | $2.0B | ||
| Q1 24 | $584.0M | $1.7B |
总债务AWKRVTY
| Q4 25 | $12.8B | — | ||
| Q3 25 | $13.0B | — | ||
| Q2 25 | $12.3B | — | ||
| Q1 25 | $13.3B | — | ||
| Q4 24 | $12.5B | — | ||
| Q3 24 | $12.6B | — | ||
| Q2 24 | $12.6B | — | ||
| Q1 24 | $12.6B | — |
股东权益AWKRVTY
| Q4 25 | $10.8B | $7.3B | ||
| Q3 25 | $10.9B | $7.4B | ||
| Q2 25 | $10.7B | $7.6B | ||
| Q1 25 | $10.5B | $7.6B | ||
| Q4 24 | $10.3B | $7.7B | ||
| Q3 24 | $10.4B | $7.9B | ||
| Q2 24 | $10.2B | $7.9B | ||
| Q1 24 | $10.0B | $7.8B |
总资产AWKRVTY
| Q4 25 | $35.4B | $12.2B | ||
| Q3 25 | $34.7B | $12.1B | ||
| Q2 25 | $33.9B | $12.4B | ||
| Q1 25 | $33.2B | $12.4B | ||
| Q4 24 | $32.8B | $12.4B | ||
| Q3 24 | $31.8B | $12.8B | ||
| Q2 24 | $31.2B | $13.4B | ||
| Q1 24 | $31.1B | $13.4B |
负债/权益比AWKRVTY
| Q4 25 | 1.18× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.26× | — | ||
| Q4 24 | 1.21× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 1.26× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $663.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-385.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -30.3% | 21.0% |
| 资本支出强度资本支出/营收 | 82.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.79× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-1.1B | $509.4M |
8季度趋势，按日历期对齐
经营现金流AWKRVTY
| Q4 25 | $663.0M | $182.0M | ||
| Q3 25 | $764.0M | $138.5M | ||
| Q2 25 | $301.0M | $134.3M | ||
| Q1 25 | $331.0M | $128.2M | ||
| Q4 24 | $639.0M | $174.2M | ||
| Q3 24 | $679.0M | $147.9M | ||
| Q2 24 | $345.0M | $158.6M | ||
| Q1 24 | $382.0M | $147.6M |
自由现金流AWKRVTY
| Q4 25 | $-385.0M | $161.8M | ||
| Q3 25 | $-33.0M | $120.0M | ||
| Q2 25 | $-432.0M | $115.5M | ||
| Q1 25 | $-217.0M | $112.2M | ||
| Q4 24 | $-255.0M | $149.8M | ||
| Q3 24 | $-4.0M | $125.6M | ||
| Q2 24 | $-325.0M | $136.6M | ||
| Q1 24 | $-227.0M | $129.7M |
自由现金流率AWKRVTY
| Q4 25 | -30.3% | 21.0% | ||
| Q3 25 | -2.3% | 17.2% | ||
| Q2 25 | -34.0% | 16.0% | ||
| Q1 25 | -19.1% | 16.9% | ||
| Q4 24 | -21.2% | 20.5% | ||
| Q3 24 | -0.3% | 18.4% | ||
| Q2 24 | -28.5% | 19.7% | ||
| Q1 24 | -22.6% | 20.0% |
资本支出强度AWKRVTY
| Q4 25 | 82.5% | 2.6% | ||
| Q3 25 | 54.8% | 2.6% | ||
| Q2 25 | 57.6% | 2.6% | ||
| Q1 25 | 48.3% | 2.4% | ||
| Q4 24 | 74.4% | 3.4% | ||
| Q3 24 | 51.4% | 3.3% | ||
| Q2 24 | 58.8% | 3.2% | ||
| Q1 24 | 60.7% | 2.7% |
现金转化率AWKRVTY
| Q4 25 | 2.79× | 1.85× | ||
| Q3 25 | 2.02× | 2.97× | ||
| Q2 25 | 1.04× | 2.49× | ||
| Q1 25 | 1.61× | 3.03× | ||
| Q4 24 | 2.67× | 1.84× | ||
| Q3 24 | 1.94× | 1.57× | ||
| Q2 24 | 1.25× | 2.87× | ||
| Q1 24 | 2.06× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AWK
| Water Services | $1.0B | 81% |
| Other | $127.0M | 10% |
| Wastewater Services | $101.0M | 8% |
| Miscellaneous Utility Charge | $11.0M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
